This announcement contains inside information
C4X Discovery Holdings plc
(“C4XD”, “C4X Discovery” or the “Company”)
Up to $402 million AstraZeneca deal for NRF2 Activator programme; Third global out-licensing deal executed
Future strategic focus to deliver high value small molecules to treat immuno-inflammatory diseases
Launched PatientSeek, a Precision Medicine platform for optimised patient selection based on its Taxonomy3® genetic analysis technology
26 April 2023 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announces its half-year results for the six months ended 31 January 2023.
Dr Clive Dix, CEO of C4X Discovery, said:
“C4XD has continued to make significant strides across our portfolio during the period, culminating in our third global out-licensing deal, this time with AstraZeneca for our NRF2 Activator programme worth up to $402 million. This external validation of our ability to generate high-quality small molecule discovery programmes builds on previous deals with globally recognised partners Sanofi and Indivior and brings our total potential deal value to $1.2 billion1.
“I’m excited that following a review of our expertise and previous successes, our strategy is now focused on treatments for immuno-inflammatory diseases. With our proven expertise in drug discovery and our rigorous approach to programme development, we believe that a more focused approach on immuno-inflammatory diseases will allow us to harness our skillset and take the development of our programmes further, providing greater value for shareholders.”
Operational Highlights (including post-period events)
Financial Highlights
Analyst webcast and conference call today
Dr Clive Dix, Chief Executive Officer, and members of the management team will host a webcast for analysts at 9:30am BST today. The webcast can be accessed online at:
A copy of the final results presentation will be released later this morning on the Company website at www.c4xdiscovery.com.
C4X Discovery Holdings plc
Mo Noonan, Communications+44 (0)7876 444 977
Panmure Gordon (UK) Limited (NOMAD and Broker) +44 (0)20 7886 2500
Freddy Crossley, Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)
C4X Discovery Media – Consilium Strategic Communications
Mary-Jane Elliott, Chris Gardner, Matthew Neal +44 (0)203 709 5700
C4X Discovery (“C4XD”) is a pioneering Drug Discovery company, combining scientific expertise with cutting-edge Drug Discovery technologies to efficiently deliver world‑leading medicines. We have a highly valuable and differentiated approach to Drug Discovery through our enhanced candidate molecule design and patient stratification capabilities, generating small molecule drug candidates across multiple disease areas focused on immuno-inflammation. Our commercially attractive portfolio ranges from early-stage target opportunities to late-stage Drug Discovery programmes and we have three commercially partnered programmes with one candidate in clinical development.
For more information visit us at www.c4xdiscovery.com or follow us on twitter @C4XDiscovery.
This website uses 'cookies' to give you the best most relevant experience. To continue you have to agree to our use of cookies policy and how and why we use cookies.
You can change which cookies are set at any time and find out more about them by reading our privacy policy.